US chip embargo backfired, made China's most valuable company

The US strategy of restricting advanced chip exports to China rested on a straightforward premise: without access to cutting-edge semiconductors, Beijing could not build competitive AI systems. However, CXMT's spectacular debut and the surge in Chinese AI funding suggest the embargo has had an unintended consequence. Rather than constraining China's AI ambitions, the export controls appear to have forced Beijing to accelerate domestic chip production and rewire its financing model entirely.

China's advantage now lies not just in chip self-sufficiency but in capital efficiency. Chinese tech firms are borrowing at 1.9% on average, more than 300 basis points cheaper than US competitors paying 5.25%—a spread that has widened to its largest since at least 2015. That cost advantage is compounding quarterly. Moreover, the shift from state subsidies to private household capital ($26 trillion in savings) represents a fundamental reorientation of how Beijing funds strategic industries. Chris Miller, author of Chip War, acknowledged to Bloomberg that while US firms have greater access to capital overall, American financing costs are rising, and the quality gap between domestic and foreign chips is closing.

The pipeline of Chinese AI IPOs suggests this is not a one-off event. DeepSeek is weighing a $71 billion valuation IPO, Moonshot AI is filing in Hong Kong, and Z.AI and MiniMax are queued next. Each listing injects capital into an ecosystem where training costs run below 10% of American equivalents and API pricing sits below 20% of global competitors. Washington's containment strategy appears to have inadvertently catalyzed the very outcome it sought to prevent.